Kineta Inc. Acquires Novel Drug Candidates from Airmid Inc. for Potential Treatment of Multiple Sclerosis, Type 1 Diabetes and other Autoimmune Diseases
7/7/2009 9:28:37 AM
SEATTLE--(BUSINESS WIRE)--Kineta, Inc. of Seattle and Airmid Incorporated of Redwood City, CA jointly announce an agreement in which a Kineta subsidiary has acquired exclusive commercial rights to a portfolio of novel therapeutic compounds from Airmid. The array of compounds holds extraordinary potential for the treatment of multiple sclerosis, type 1 diabetes mellitus and numerous other autoimmune diseases.
comments powered by